In addition, SLC7A11 overexpression was an adverse factor for the DSS of patients with eight cancers (ACC, BLCA, KICH, KIRC, KIRP, LGG, PRAD, and SKCM) (HR > 1, p < 0.05); however, it was a favorable factor for better DSS in READ (HR < 1, p < 0.05) (Figure 2B and Figure 2F). Here, SLC7A11 is linked to cancer.